Sanofi says charged in birth defects case

Pharmaceutical firm Sanofi has been charged in France with failure to adequately warn patients and causing injury over an anti-epilepsy drug linked to birth defects following a three-year probe.

The French group said in a statement late Monday that prosecutors had decided to move forward on charges of aggravated fraud and unintentionally causing injury.

Under the French legal system, the charges do not automatically mean the case will reach a courtroom as prosecutors could decide not to move to trial. The investigation, launched in September 2016 following legal action by victims and their families, sought to determine whether Sanofi misled doctors and patients about the dangers of the drug valproate - marketed around the world as Depakine, Depakote, Stavzor and other trade names - and thus caused injuries to patients. Two French government agencies had earlier concluded that Sanofi had not sufficiently warned about known risks to having pregnant women take the drug.